Increased activity of phospholipase A2 (PLA2) in the ileal mucosa may contribute to the inflammation in Crohn's disease. The results of this study showed that (a) three months after ileocolonic resection for Crohn's disease the neoterminal ileal mucosa showed endoscopically new inflammation and had higher PLA2 activity than at the time of the operation (n=8); no such findings were seen in controls (n=7), (b) histologically normal ileal mucosa (n=3) contained mRNA for three isoforms of PLA2 (PLA2-I, PLA2-II, and cPLA2), but the amounts ofPLA2-II mRNA clearly exceeded the amounts ofmRNA for PLA2-I and cPLA2, (c) ileal mucosa from Crohn's patients (n=2) contained higher values ofPLA2-II mRNA than ileal mucosa from two controls, (d) ileal mucosa from Crohn's patients (n=4) showed increased PLA2-II mRNA three months after ileocolonic resection. In conclusion, these results show that the predominating PLA2 mRNA in the human ileal mucosa is type II PLA2, and that increased synthesis of PLA2-II might be responsible for the increased PLA2 activity found in the ileal mucosa accompanying recurrent ileal inflammation in Crohn's disease.
Phospholipase A2 (PLA2) is a key enzyme in the formation of arachidonic acid metabolites, platelet activating factor, and lysophosphatidylcholine,l all of which may take part in inflammatory reactions in the gastrointestinal tract.2 Accordingly, the activity of PLA2 was found to be increased in the ileal mucosa of patients with Crohn's disease, and the increased PLA2 activity was associated with early symptomatic recurrent ileal inflammation after surgery.3 Furthermore, although there was endoscopically detectable inflammation specific for Crohn's disease already three months after ileocolonic resection,4 an increase in mucosal PLA2 activity was found to precede the endoscopically detectable inflammation. 5 These findings suggest that activation of intestinal PLA2 may play a part in the pathogenesis of Crohn's disease, although the underlying mechanisms remain to be clarified. Until now, three genetically different forms of PIA2 have been identified: two low molecular weight PLA2, group I PIA2 (PIA2-I) and group II PIA2 (PLA2-II), and one high molecular weight, cytosolic PLA2 (cPIA2).' PLA2-I is found in large amounts in the pancreas and is thought to serve mainly as a digestive enzyme. The presence of PLA2-I, however, in other organs than the pancreas, such as the lung,6
suggests that PIA2-I may have additional, yet unidentified, physiological functions. PIA2-II has been found both associated with cells and tissues and secreted extracellularly. For example, PIA2-II has been found in secretory granules of the small intestinal Paneth cell,7 8 increased amounts of PLA2-II have been shown in rheumatoid synovial fluid,9 and in psoriatic tissue.'0 High values of PLA2 activity in serum from patients with Crohn's disease or ulcerative colitis, have been attributed to PLA2-1, and correlated with disease activity." l The high molecular weight cPLA2 has been identified in various inflammatory cells like human platelets, polymorphonuclear leucocytes, and monocytes'2-14 and is thought to play an important part in receptor mediated signal transduction, arachidonic acid liberation, and eicosanoid production. '5 It is not known in detail which type(s) of PLA2 are present in the human ileal mucosa, or which type(s) could be responsible for the raised ileal PLA2 activity found in patients with Crohn's disease.
The aim of this study was threefold: (a) to determine the activity of PLA2 in the ileal mucosa in relation to the development of recurrent inflammation after ileocolonic resection for Crohn's disease, (b) to clarify which type(s) of PLA2 are present in ileal mucosa, and (c) to examine which type(s) of PLA2 could be responsible for the raised PLA2 activity seen in the ileal mucosa of patients with Crohn's disease. We investigated the endoscopic appearance and mucosal PLA2 activity of the ileal resection margin, at the time of ileocolonic resection and at follow up three months later. In addition, the mRNA expression of different PLA2 enzymes (PLA2-I, PIA2-II and cPLA2) was studied in a small number of patients with Crohn's disease and patients without inflammatory bowel disease.
Methods

Subjects
Mucosal samples for measurements of PLA2 activity were obtained from the ileum of 15 patients operated on with ileocolonic resection. Eight of these (five men and three women, 17-55 years, mean 35) had Crohn's disease and seven (five women and two men, 43-77 years, mean 66) had colonic cancer. Intraoperatively, the appearance of the ileum was evaluated endoscopically and mucosal biopsy specimens were taken for PLA2 analysis. The patients were followed up three months after the operation, with colonoileoscopic examination.5 At that time the severity of recurrent inflammation was assessed by an endoscopic score and new mucosal biopsy specimens were collected for PLA2 analysis. The biopsy samples were frozen in liquid nitrogen and kept at -70°C until analysis.
To study expression of PLA2 on the mRNA level, RNA was isolated from the ileal mucosal resection margin of four of the patients described above (17-55 years, mean 38, Figs [4] [5] [6] . From these four patients, RNA was also isolated from the same area, obtained at endoscopic follow up after three months. In addition, RNA was isolated from the distal ileum of two other patients with Crohn's disease (30 and 40 years, one macroscopically normal and one macroscopically inflamed) and two patients with colonic neoplasm (74 and 81 years, both macroscopically normal, Fig 3) . RNA was also isolated from the proximal colon of a patient with colonic neoplasm (79 years, macroscopically normal, Fig 1) .
After surgical removal, the bowel specimen was kept on ice, both during transport to the laboratory and while the mucosa was scraped off the muscularis layer. RNA preparations were started within 30 minutes after surgical removal. Biopsy samples were frozen in liquid nitrogen and kept at -70°until analysis.
Ethics
The study was approved by the ethics committee of human experimentation, Linkoping. Northern blots Separation of different sized RNA fragments was performed in a denaturing system as previously described19 and the fragments transferred to positively charged nylon membranes (Boehringer Mannheim). The original method was modified by labelling the specific oligonucleotide probe, corresponding to base pairs 271-300 in the human PLA2-II complementary deoxyribonucleic acid, with DIG (digoxigenin) oligonucleotide tailing system according to the manufacturer's instructions (Boehringer Mannheim, Mannheim, Germany). The membrane with bound RNA was prehybridised (60°C) for one hour in a solution containing 0.39 M sodium chloride, 0.03 M sodium citrate, 1% blocking reagent, 0/1% N-lauroylsarcosine, and 0.02% laurylsulphate. The PLA2 hybridisation reaction was then carried out in a solution as previously described and with the addition of 10 nM labelled probe (60°C) for three hours. The membrane was washed and the hybridised product was detected with DIG Luminescent system according to the manufacturer's instructions (Boehringer Mannheim). The resulting blots were subjected to autoradiography on Cronex 4 x ray film with intensifying screens (Du Pont de Nemours, Bad Homburg, Germany) at room temperature for 5-30 minutes before development.
Polymerase chain reaction (PCR) assisted mRNA amplification First strand cDNA synthesis RNA was denatured at 70°C for five minutes and then chilled on ice. One ,ug total RNA was transcribed to cDNA in a final volume of 20 ,ul master mix solution containing 5 mM MgCl2, lx PCR buffer II (50 mM KCI and 10 mM TRIS HCl, pH 8R3), 1 mM of each nucleotide (dGTP, dATP, dTTP, and dCTP), 1 U/,1 RNase inhibitor, 2.5 U/4l reverse transcriptase, and 2.5 ,uM random hexamers. The reaction mixture was incubated at 20°C for 10 minutes, 42°C for 15 minutes, 99°C for five minutes, and 5°C for five minutes (GeneAmp RNA PCR Kit, Perkin-Elmer, Roche In an attempt to get optimal conditions for comparison between samples, different numbers of amplification cycles were tested for each group of PLA2. The same batch of reverse transcribed total RNA was divided for use in the analysis of PLA2-I, PLA2-II, and cPLA2. Also, the number of cycles used in the amplification of the PCR product, was chosen to give optimal resolution.
Statistical analysis
Comparative statistical analysis was made with Wilcoxon rank sum test (between the groups), and with Wilcoxon signed rank test (within the groups), with p<005 considered significant.
Results
Ileal PLA2 activity and endoscopic appearance in Crohn's disease Three months after ileocolonic resection for Crohn's disease, the PLA2 activity was significantly increased in the preanastomotic ileal mucosa compared with the mucosa obtained from the same area at the time of resection (Table II) . No such difference was found in controls (patients resected for colonic cancer) (Table II) . Moreover, three months after ileocolic resection, the PLA2 activity in ileal mucosa from Crohn's disease patients was significantly higher than in the controls. No macroscopical signs of inflammation were seen at the resection margin at the time of operation in Crohn's disease patients or controls (score = 0), while after three months postoperatively, all Crohn's disease patients showed recurrent ileal inflammation (scores between 1 and 4, median 2). No endoscopic signs of inflammation were seen in the control group (score= 0).
Ileal PLA2 mRNA expression With northern blot analysis, PLA2-II mRNA was easily detected in histologically normal mucosal samples from the distal ileum and proximal colon. As Fig 1 shows, 10 Kig of purified mRNA.
By contrast, PCR assisted mRNA amplification permitted the detection of PLA2-I and cPLA2 together with PLA2-II mRNA in histologically normal ileal mucosa (Fig 2) . mRNAs for PLA2-I, PLA2-II, and cPLA2 were also found in histologically normal gastric and colonic mucosa (data not shown).
Northern blot analysis of samples from the distal ileum showed higher PLA2-II mRNA expression in two Crohn's disease patients than in two patients with non-inflammatory bowel disease (Fig 3) . Both the macroscopically inflamed and the macroscopically normal mucosa of the Crohn's disease patients, showed increased PLA2-II mRNA expression when compared with patients with non-inflammatory bowel disease (Fig 3) .
The ileal mRNA expression of PLA2-I, PLA2-II, and cPLA2 was studied in four of the patients with Crohn's disease, previously investigated for ileal PLA2 activity at ileocolonic resection and at follow up three months later (Table II amplification) (Fig 4) . Furthermore, although mRNA for PLA2-I could be detected in all samples after 50 cycles PCR amplification, no clear pattern appeared as to differences between the time of resection and after three months (Fig 5) . As Fig 6 shows , it was possible to detect mRNA for cPLA2 in two of the investigated samples at the time of resection and in one sample after three months (55 cycles PCR amplification). No clear pattern was seen as to differences in cPLA2 mRNA between samples at the time of resection and after three months (Fig 6) .
Discussion
The rate of postoperative recurrence is high in Crohn's disease, and recurrent ileal inflammation has been found in the neoterminal ileum three months after ileocolonic resection. 4 We previously found that PLA2 activity was increased in the ileal preanastomotic area, suggesting a role for PLA2 in the development of the new inflammatory lesions.5 The results of our investigation confirm and extend these previous findings. Thus, the PLA2 activity was found to be normal in endoscopically normal ileal mucosa at the time of operation and a raised PLA2 activity was found accompanying ileal recurrent inflammation after three months (Table II) . Thus, the PLA2 activity does not seem to be generally increased in the ileal mucosa of patients with Crohn's disease. It may be inferred, therefore, that increased PLA2 activity accompanies an ongoing inflammatory process, which starts in the neoterminal ileum, close to the new junction. It is possible that the close proximity to the colon, with the possibility of reflux of colonic substances, might be harmful to ileal mucosa. 5 (Fig 1) . The With northern blot technique, we could not detect PLA2-I or cPLA2 in ileal mucosa, not even after purification of the samples to pure mRNA fractions. Because of these striking differences in detection possibilities, it can be deduced that there are, in the human ileal mucosa, great differences in the values of mRNA expression between PLA2-II and PLA2-I or cPLA2. Obviously, the mRNA expression of PLA2-II greatly supersedes that of PLA2-I and cPLA2. On the other hand, PCR assisted mRNA amplification enabled detection of both group I and cPLA2, besides PLA2-H, in histologically normal ileal mucosa (Fig 2) and three types of PLA2 could also be detected in gastric and colonic mucosa. In an attempt to compare PLA2-I, PLA2-II, and cPLA2 in biopsy specimens of normal and inflamed mucosa, we analysed mRNA expression for all three types of PLA2 after PCR assisted mRNA amplification (Figs 4-6 In summary, we have found that the distal ileum is rich in PLA2-II mRNA and that the expression of this mRNA and the corresponding enzyme activity accompanies recurrent new ileal inflammation as soon as three months after ileocolonic resection for Crohn's disease. As far as we know, this is the first study in which endoscopic findings and PLA2 enzyme activity are related to group I, group II, and cPLA2 mRNA expression within the same patient at the time of ileocolonic resection and at the same locality at follow up on a later occasion. This study does not clarify, however, which particular cell type(s) is responsible for the increased PLA2 activity and mRNA expression. This problem might be considered by using in situ hybridisation and immunohistochemical studies of normal and diseased tissue. 
